Company
Every investor coverage indicates participated in a round Spinifex raised.
Investors whose own portfolio pages list Spinifex, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
The transaction that ended Spinifex's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Novartis International | Acquisition | 29 Jun 2015 | $267m | Startup Daily, AFR Technology |
Companies Spinifex acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Spinifex. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UniSuper commits $75 million to Uniseed, the research commercialisation fund owned by four universities and CSIRO, its first venture investment; past portfolio sales to Schneider Electric, RTP Co and Novartis are recalled.
Birchal's CSF Yearbook 2021 found Australian equity crowdfunding hit record levels in 2021, with $71 million raised across 89 companies, and recalls Biome Australia becoming the first CSF-backed business to join the ASX.
Swiss pharmaceutical giant Novartis has agreed to acquire Australian drug developer Spinifex Pharma for $US200 million upfront, with up to $US500 million more in milestone payments.
Also Startup Daily